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ABSTRACT
Introduction: Data regarding the prevalence of 
immune thrombocytopenia (ITP) is limited, and 
is derived from North American population-
based analyses. Therefore, the authors 
conducted the first study outside the United 
States (US) using the United Kingdom (UK) 
General Practice Research Database (GPRD) to 
estimate the adult prevalence of ITP in the UK. 
Methods: This study estimated the diagnosed 
prevalence of ITP in the adult population 
in UK using the GPRD from January 1, 
1992 to December 31, 2009. Results: The 
unadjusted, overall 18-year period prevalence 
was 50.29/100,000 (95% CI: 48.51, 52.06). 
The age- and gender-adjusted, overall 18-year 
period prevalence was 50.00/100,000 (95% CI: 
49.20, 50.90). ITP prevalence was lower in adults 
aged 18-49 years of age (30.09/100,000, 95% 
CI: 28.27, 31.90) than in older adults aged 50-64 
years of age (58.22/100,000, 95% CI: 53.88, 
62.57) or ≥65 years of age (93.80/100,000, 
95% CI: 88.76, 98.85). Prevalence was higher 
among females (59.32/100,000, 95% CI: 56.63, 
62.01) than in males (40.66/100,000, 95% 
CI: 38.36, 42.96). Prevalence in the GPRD 
increased over time (1992 [16.33/100,000, 95% 
CI: 13.70, 19.00], 2000 [36.93/100,000, 95% CI: 
34.50, 39.30], and 2009 [58.49/100,000, 95% 
CI: 55.80, 61.20]). Conclusion: This new analysis 
of general practice in the UK provides robust 
prevalence estimates of diagnosed ITP among 
adults in Europe. ITP prevalence is higher in 
women and increases with age and over time. 
Keywords: General Practice Research Database; 
immune thrombocytopenia; observational data; 
prevalence; United Kingdom
INTRODUCTION
Immune thrombocytopenia (ITP) is an 
autoimmune disorder of adults and children 
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that is characterized by decreased platelet 
count (<100×109/L), most commonly resulting 
from autoantibody-mediated peripheral 
platelet destruction and suboptimal platelet 
production.1-6 Among children, ITP is typically 
acute in duration (<6 months), while in adults it 
is usually a chronic condition lasting for many 
years6-11 with associated bruising, petechiae,7 and 
increased risk of clinically significant bleeding.6
Although ITP in adults can and does go into 
remission, patients are not considered ‘cured’ 
since the condition often relapses.12
ITP is a rare disease and knowledge of 
its incidence and prevalence is important, 
specifically to improve our understanding of 
the natural history of this disease. Current 
literature on the descriptive epidemiology of ITP 
is limited, and derives primarily from European, 
North American, and Japanese population-based 
studies. In published ITP incidence reports, 
estimates of adult ITP ranged from 1.6-3.9 per 
100,000 adults per year in the United States 
(US), the United Kingdom (UK), and Japan.13-18
Due to the chronic nature of adult ITP12 and 
the consequent accumulation of cases in the 
population, available prevalence estimates 
are appreciably higher,12,19-21 ranging from a 
1-year prevalence of 9.5 per 100,000 persons21
to a high of 189.3 per 100,000 persons in a 
hospital-based study conducted in a US Veterans 
Administration patient population.20 To the 
authors’ knowledge, there are no published 
estimates of the prevalence of adult ITP outside 
of the US.19-21 Therefore, using the General 
Practice Research Database (GPRD),22 the authors 
conducted the first study outside the US and 
estimated the prevalence (per 100,000 persons) 
of adults with a diagnosis of ITP in the GPRD 
from 1992-2009, unadjusted overall as well as 
age- and gender-specific (ie, adjusted to the 
2009 UK population). In addition, the authors 
estimated the period prevalence of adults with a 
diagnosis of ITP for each year from 1992-2009, 
overall and stratified by gender. 
MATERIALS AND METHODS
Source of Data
This was a retrospective study using 
observational data from the GPRD; an electronic 
medical records database of a representative 
sample of general practices throughout the UK.22
The database currently includes information on 
diagnoses, prescriptions, referrals, outcomes, 
and laboratory results together with basic 
demographic information for approximately 
9.6 million “research standard” patients from 
over 610 centers. The database is population-
based and representative of the age, sex, and 
geographic regions of the UK.22 Inclusion 
is based on registration with a contributing 
general practice, rather than consultations, 
and there is no requirement that patients be 
actively receiving treatment to be considered 
for the database. Data are stored using Read 
codes for diseases that are cross-referenced to 
the International Classification of Diseases 
(ICD-9).23 GPRD coding has been subject to a 
number of validation studies, which have found 
it an accurate identification tool for a wide 
spectrum of conditions and diseases.17,24-26 The 
quality of GPRD data is continuously monitored 
by the UK Medicines and Healthcare Products 
Regulatory Agency (MHRA). General practices 
are considered to be “up to (research) standard” 
and are included in the GPRD if they meet a 
series of quality checks on completeness and 
consistency of information that the general 
practice provides. Practices failing to meet these 
standards are excluded from participation. The 
study protocol was approved by the Independent 
Scientific Advisory Committee (ISAC) of the 
GPRD for the MHRA.
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Study Population
The study period ran from January 1, 1992 to 
December 31, 2009. Patients were included in 
the study if they provided at least 1 year of up-to-
standard follow-up during the study period. 
Prevalent ITP cases included all adult individuals, 
aged ≥18 years, with at least one diagnostic Read 
code (42P2.11, D313.12, D313000, D313012) for 
ITP in the patient’s medical records in the GPRD. 
Follow-up could start prior to the 18th birthday; 
however, ITP diagnosis must be on or after the 
18th birthday. 
Statistical Analyses
The overall prevalence of ITP in 1992-2009 was 
calculated as the total number of identified adult 
ITP cases from the population of all adults in 
the GPRD database, with at least 1 year of up-to-
standard follow-up between 1992-2009, and 
then expressed as the number of ITP cases per 
100,000 persons. Period prevalence for each year 
from 1992-2009 was calculated as the number 
of prevalent ITP cases within the population of 
all adult patients with continuous registration 
throughout that given calendar year, and then 
expressed as the number of ITP cases per 100,000 
persons. Prevalent cases included all adult patients 
with a record of ITP during, or any time before, 
the current period of observation. Prevalence was 
calculated and stratified by gender as well as by the 
following age categories: 18-49 years, 50-64 years, 
18-64 years, ≥65 years, and ≥18 years (all adults). 
CIs were calculated based on the binomial 
distribution. The overall age- and gender-
adjusted prevalence and 95% CI were calculated 
by direct standardization to the age- and gender-
distribution of the 2009 UK population.25
GPRD physicians are not required to re-enter 
ongoing diagnoses unless there is some change 
in the patient’s status, such as worsening of the 
condition or a new treatment. Hence, to better 
understand recording trends over time, the 
authors calculated a 1-year period prevalence as 
the proportion of patients with ITP mentioned in 
that calendar year for each year individually from 
1992-2009. The numerator for the 1-year period 
prevalence consisted of patients with ITP explicitly 
mentioned in that year (either newly diagnosed 
ITP cases or patients with previously diagnosed 
ITP who had an additional record for ITP in that 
calendar year). Previously diagnosed ITP patients 
without an ITP record in the current calendar year 
were not included in that year’s period prevalence. 
The denominator included everyone followed in 
the GPRD for that calendar year.
RESULTS
Table 1 presents age- and gender-specific 
adult ITP prevalence and 95% CIs in the 
UK. The unadjusted, overall 18-year period 
prevalence was 50.29/100,000 (95% CI: 
48.51, 52.06) persons for the 1992-2009 time 
period. The age- and gender-adjusted, overall 
18-year period prevalence was 50.00/100,000 
(95% CI: 49.20, 50.90) persons or 24,337 
(95% CI: 23,948-24,775) diagnosed adult 
cases of ITP in the UK in 2009. ITP prevalence 
was lower in adults aged 18-49 years of 
age (30.09/100,000, 95% CI: 28.27, 31.90) 
than in older adults aged 50-64 years of age 
(58.22/100,000, 95% CI: 53.88, 62.57) or 
≥65 years of age (93.80/100,000, 95% CI: 88.76, 
98.85). Prevalence was higher among females 
(59.32/100,000, 95% CI: 56.63, 62.01) than in 
males (40.66/100,000, 95% CI: 38.36, 42.96). 
Prevalence in the GPRD rose over time (1992 
[16.33/100,000, 95% CI: 13.70, 19.00], 1995 
[21.91/100,000, 95% CI: 19.30, 24.50], 2000 
[36.93/100,000, 95% CI: 34.50, 39.30], 2005 
[49.39/100,000, 95% CI: 46.90, 51.90], and 
2009 [58.49/100,000, 95% CI: 55.80, 61.20]) 
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95% CI: 2.10, 4.50], 1995 [1.97/100,000, 95% 
CI: 1.20, 2.80], 1998 [3.05/100,000, 95% CI: 2.20, 
3.90] vs. 2000 [4.51/100,000, 95% CI: 3.70, 5.40], 
2005 (4.40/100,000, 95% CI: 3.70, 5.10], 2009 
(4.57/100,000, 95% CI: 3.80, 5.30]) (Figure 2). 
Table 1. Eighteen-year period prevalence of diagnosed adult immune thrombocytopenia (ITP) by age and gender in the 
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3513085 1057 30.09 (28.27, 31.90)
50-64 1183364 689 58.22 (53.88, 62.57)
≥65 1414667 1327 93.80 (88.76, 98.85)
All 6111116 3073 50.29 (48.51, 52.06)
18-49
Female
1776034 699 39.36 (36.44, 42.27)
50-64 581523 410 70.50 (63.68, 77.33)
≥65 794795 761 95.75 (88.95, 102.55)
All 3152352 1870 59.32 (56.63, 62.01)
18-49
Male
1737051 358 20.61 (18.47, 22.74)
50-64 601841 279 46.36 (40.92, 51.80)
≥65 619872 566 91.31 (83.79, 98.83)
All 2958764 1203 40.66 (38.36, 42.96)







































Figure 1. Eighteen-year period prevalence of adults with a diagnosis of immune thrombocytopenia (ITP) (per 100,000 
persons) in the General Practice Research Database (GPRD) population, 1992-2009. 
(Figure 1). The pattern across the 1-year period 
prevalences demonstrate that the proportions 
of patients with ITP explicitly mentioned in any 
given year was higher in the second half of the 
study than the first half (1992 (3.29/100,000, 
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DISCUSSION
Using a large population-based data source,22
these results provide evidence that the prevalence 
of diagnosed adult ITP is higher in females 
(59.32/100,000) than males (40.66/100,000), 
especially in the 18-49 years and 50-64 years age 
groups. These results are in line with previously 
published data reporting increased prevalence 
with advancing age and a higher prevalence 
among women.12
Results from this study also suggest an 
increase in diagnosed ITP over time, with 
a prevalence of 16.33, 36.93, and 58.49 per 
100,000 persons in 1992, 2000, and 2009, 
respectively (Figure 1). The observed overall 
increase in prevalence from 1992-2009 may 
be related to the increase in incidence of ITP 
reported in a study by Schoonen et al. using the 
same GPRD database.17 Specifically, Schoonen 
reports a higher incidence of ITP in the period 
2000-2005 compared to the periods 1990-
1994 and 1995-1999. This increased incidence 
after 2000 may be a contributing factor to the 
increased prevalence seen in the present study. 
In addition, the increase in prevalence may be 
due, in part, to increased awareness of the disease 
among physicians, more efficient diagnostic 
practices, and newly available therapies. It is 
possible that the increasing prevalence of adult 
ITP may be due, in part, to patients studied 
in the later years having longer accumulated 
medical histories and, hence, there is a greater 
opportunity of identifying all existing cases later 
in the study. On average, patients followed in 
1992 had ≥3 years of prior history, while those 
followed in 2009 had ≥9 years of available 
information (data not shown). However, the 
1-year period prevalence figures looking only at 
ITP records within the current year suggest that 
more patients had ITP records within the later 
years, irrespective of available medical history. 
Additionally, if the shorter available history had 
led to some existing prevalent cases failing to 
be identified in the early years, the incidence of 
ITP would be greater in the early years due to the 









































Figure 2. Period prevalence of adults with a diagnosis of immune thrombocytopenia (ITP) (per 100,000 persons) in the 
General Practice Research Database (GPRD) population 1992-2009. 
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misclassification of existing patients as incident 
cases. This is not supported by the increase in 
incidence over time noted by Schoonen et al. 
These observations suggest that the overall 
increasing trend in prevalence is not solely an 
artefact of data collection or analysis, but rather 
is driven by an underlying increase in disease 
diagnosis. The authors believe that the later 
figures may be more likely to reflect the “true” 
prevalence of ITP diagnosed in adults, given an 
assumption that ITP in adults is essentially a 
chronic disease that may persist indefinitely.9-11,27
Previously, the authors analyzed the Integrated 
Healthcare Information System (IHCIS) database, 
one of the largest US-managed healthcare claims 
databases, with over 70 million patients from 
more than 45 health plans. The authors reported 
a prevalence of diagnosed adult chronic ITP of 
23.6 (95% CI: 23.4-23.8) per 100,000 adults, 
where prevalence of chronic ITP increased with 
age and was higher among females.19 This current 
analysis of GPRD data indicates the same pattern; 
prevalence of ITP was much higher in females in 
age groups 18-49 years and 50-64 years, than in 
males of similar ages. This was expected, given 
the female preponderance in ITP incidence.17,28
In GPRD, the difference in prevalence between 
elderly female patients ≥65 years of age 
(95.75/100,000, 95% CI: 88.95, 102.55) and 
males of a similar age (91.31/100,000, 95% 
CI: 83.79, 98.83) was less pronounced. 
An analysis of the published ITP prevalence 
data requires careful consideration of case 
definitions and different methodologies 
employed, including different periods of data 
collection. Previous published reports indicated 
period prevalences between 9.5-189.3/100,000, 
for varying periods and populations; period 
prevalence within the present study was 
positioned within this range, 50.29/100,000. It 
is important to note that all previous published 
studies of ITP prevalence used cases defined by 
administrative data,19-21 whereas cases within the 
present study were defined by electronic medical 
records. In addition, earlier data were from the 
US, whilst these were from the UK.
The authors believe this is the largest robust 
study to estimate the prevalence of ITP using 
a population database such as the UK GPRD. 
The present study has several strengths. First, 
the Read codes used to identify ITP codes 
are likely to reflect recording in UK general 
practice, having been reviewed by a physician 
with extensive experience managing adult 
patients with ITP in the UK National Health 
Service (NHS), who also formulated the 
strategy for the previous study using the 
UK GPRD.29 Recording guidelines for GPRD 
encourage general practitioners (GPs) to 
enter signs and symptoms initially and only 
record a diagnosis, in this case a diagnosis of 
ITP, when there is a high diagnostic certainty. 
Exclusion diagnoses are not used routinely. 
GPs are also the point of entry to healthcare 
services in the UK and are encouraged to add 
all information deemed important for the 
ongoing clinical care of the patient, including 
diagnostic information from specialist services 
(eg, hematologists). Therefore, this data source 
is likely to capture ITP diagnoses reliably and be 
less sensitive to some recording issues, such as 
rule-out diagnoses, seen in other observational 
data. Second, the validity of coded records to 
identify ITP patients correctly has previously 
been confirmed by a review of the source 
medical records. In a study by Schoonen et al., 
validation of the computerized diagnosis of 
ITP against the source paper medical records 
indicated a high positive predictive value 
(PPV) of 91% (95% CI: 84%-96%).17
One limitation of the present study is that 
the GPRD coding system does not contain codes 
for ITP remission nor relapse; therefore, patients 
with acute ITP and patients with chronic ITP 
1102 Adv Ther (2011)  28(12):1096-1104.
were not able to be distinguished. However, 
chronic ITP is generally reported to represent the 
majority of ITP in adults;9,27 therefore, all chronic 
ITP cases in adults will most likely be captured 
with minimal overestimation of chronic ITP 
through the inclusion of acute cases. 
Previously, the authors calculated an annual 
ITP prevalence in a US data source (where each 
consultation generates a new record of ITP) based 
on patients with an ITP record within the year 
of interest.19 In GPRD, diagnoses are routinely 
entered only once and considered ongoing unless 
the patient’s status changes. Additional records 
may only be prompted by clinically important 
events, such as worsening of the condition or 
communication from specialists. The authors 
provide details of the annual “period” prevalence 
here in an attempt to provide additional insights 
into the temporal trend in ITP recording 
(Figure 2). However, the authors believe this 
underestimates true prevalence in GPRD since 
there is no requirement to re-enter “ongoing” 
diagnoses. “True” prevalence is presented based 
on any previous record of adult ITP within the 
patient’s records.
For most patients with ITP and/or the 
patient’s caregivers, effective management of 
the disease requires an understanding of the 
natural history of ITP, which often comes via 
counseling from healthcare providers. Improved 
understanding of the natural history of ITP 
among healthcare practitioners, such as GPs 
enrolled in the GPRD, will therefore assist ITP 
patients in making better informed choices 
regarding treatment and overall health, and 
substantially improving quality of life. 
CONCLUSION
In conclusion, the present study provides a 
robust population-based prevalence estimate 
of ITP among adults, and indicates that ITP 
prevalence increases with age and is higher in 
women. It also suggests an increasing prevalence 
over time of adults with a diagnosis of ITP. 
Moreover, educating and counseling patients 
with ITP and/or the patient’s caregivers requires 
an understanding of the natural history of ITP; 
thus, this recent analysis of the prevalence of 
ITP in general medical practices in the UK adds 
another piece of important epidemiological 
evidence to our understanding of the natural 
history of this rare disease. 
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